Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
NYSE:GSK
Total Valuation
GlaxoSmithKline has a market cap or net worth of $81.17B. The enterprise value is $97.13B.
Market Cap$81.17B
Enterprise Value$97.13B
Share Statistics
GlaxoSmithKline has 2,033,977,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,033,977,000
Owned by Insiders―
Owned by Institutions10.50%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 8.51%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)8.51%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee457.18K
Profits Per Employee43.00K
Employee Count68,629
Asset Turnover0.53
Inventory Turnover1.60
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 18.6. GlaxoSmithKline’s PEG ratio is ―.
PE Ratio18.6
PS Ratio―
PB Ratio―
Price to Fair Value4.03
Price to FCF―
Price to Operating Cash Flow7.59
PEG Ratio―
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 31.38B and earned 2.58B in profits. Earnings per share was 1.26.
Revenue31.38B
Gross Profit22.33B
Operating Income4.02B
Pretax Income3.48B
Net Income2.58B
EBITDA6.67B
Earnings Per Share (EPS)1.26
Cash Flow
In the last 12 months, operating cash flow was 7.72B and capital expenditures -3.06B, giving a free cash flow of 4.67B billion.
Operating Cash Flow7.72B
Free Cash Flow4.67B
Free Cash Flow per Share2.29
Dividends & Yields
GlaxoSmithKline pays an annual dividend of $0.428, resulting in a dividend yield of 4.05%
Dividend Per Share$0.428
Dividend Yield4.05%
Payout Ratio38.22%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.30
52-Week Price Change4.02%
50-Day Moving Average38.67
200-Day Moving Average36.82
Relative Strength Index (RSI)57.60
Average Volume (3m)3.55M
Important Dates
GlaxoSmithKline upcoming earnings date is Oct 29, 2025, Before Open (Confirmed).
Last Earnings DateJul 30, 2025
Next Earnings DateOct 29, 2025
Ex-Dividend DateAug 15, 2025
Financial Position
GlaxoSmithKline as a current ratio of 0.78, with Debt / Equity ratio of 117.33%
Current Ratio0.78
Quick Ratio0.52
Debt to Market Cap0.29
Net Debt to EBITDA1.99
Interest Coverage Ratio6.28
Taxes
In the past 12 months, GlaxoSmithKline has paid 526.00M in taxes.
Income Tax526.00M
Effective Tax Rate0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 18.52, with an EV/FCF ratio of 34.57.
EV to Sales3.94
EV to EBITDA18.52
EV to Free Cash Flow34.57
EV to Operating Cash Flow18.84
Balance Sheet
GlaxoSmithKline has $3.62B in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.62B billion.
Cash & Marketable Securities$3.62B
Total Debt$0.00
Net Cash$3.62B
Net Cash Per Share$1.78
Tangible Book Value Per Share-$4.62
Margins
Gross margin is 71.69%, with operating margin of 12.82%, and net profit margin of 8.21%.
Gross Margin71.69%
Operating Margin12.82%
Pretax Margin11.08%
Net Profit Margin8.21%
EBITDA Margin21.25%
EBIT Margin13.12%
Analyst Forecast
The average price target for GlaxoSmithKline is $43.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$43.33
Price Target Upside6.54% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast3.46%
EPS Growth Forecast-13.29%